Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain

Next Previous
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LX 9211 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RELIEF-DPN 1
  • Sponsors Lexicon Pharmaceuticals

Most Recent Events

  • 07 Aug 2024 According to a Lexicon Pharmaceuticals media release, data from sub study will be presented at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024.
  • 19 Jun 2024 According to a Lexicon Pharmaceuticals media release, the company announced that Diabetes Care, the peer-reviewed journal of the American Diabetes Association, has published a research paper on this trial
  • 18 Jun 2024 According to a Lexicon Pharmaceuticals media release, three poster presentations including results for substudy will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top